Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Number of ongoing Clinical Trials (for drugs) involving Endometriosis by Phase

  • There are currently 118 ongoing clinical trials involving Endometriosis

  • Of the 118 trials,41 trials are in Phase II

  • Furthermore, 30 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Endometriosis by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Endometriosis, a women’s health condition. The largest number of ongoing clinical trials for Endometriosis is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions engaged in Endometriosis-related drug trials.

Endometriosis related clinical trials sponsors

Obstetrics & Gynecology Hospital of Fudan University, Bayer AG, Longhua Hospital Shanghai University of TCM, Ferring International Center SA, and Evotec SE are a few notable clinical trial sponsors involved in Endometriosis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Endometriosis

Leuprolide acetate (Tapros, Tapros 3M Depot, Lupron Depot), Goserelin (Zoladex, Goserelin Depot, Gosegyne), and Drospirenone and Ethinylestradiol (Yasmin/ Yasminelle/ Convuline, Flexyess) are among the key marketed drugs involving Endometriosis.

Leuprolide acetate (Tapros, Tapros 3M Depot, Lupron Depot) is a gonadotropin-releasing hormone (GnRH) analog. It functions via Gonadotropin-Releasing Hormone Receptor (GNRHR) Agonist mechanism of action. It is formulated as a solution and lyophilized powder for suspension for subcutaneous and intramuscular administration. It is indicated in the palliative treatment of advanced prostatic cancer, advanced breast cancer, endometriosis, including pain relief and reduction of endometriotic lesions. Leuprolide acetate was first approved in 1985 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by AbbVie Inc.

Goserelin (Zoladex, Goserelin Depot, Gosegyne) is a luteinising hormone-releasing hormone agonist. It functions via Gonadotropin-Releasing Hormone Receptor (GNRHR) Agonist mechanism of action. It is formulated as an implant for subcutaneous use. Zoladex is indicated for the palliative treatment of patients with hormone-dependent advanced carcinoma of the prostate (Stage M1 or Stage D2), for use in combination with a nonsteroidal antiandrogen and radiation therapy for the management of locally advanced (T3, T4) or bulky Stage T2b, T2c carcinoma of the prostate, as adjuvant hormone therapy to external beam irradiation for patients with locally advanced prostate cancer. Goserelin was first approved in 1987 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by TerSera Therapeutics LLC.



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward